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Section A. MRI protocols 
Cardiac MRI Protocol 
Short axis images from the atrio-ventricular ring to the LV apex were acquired using a 2D
retrospectively  ECG-gated  breath  hold  segmented  SSFP cine  sequence  with  retrospective
gating. The imaging parameters were repetition time (TR)  = 3.34ms and echo time (TE) =
1.46 ms, and 52o flip angle, and the image stack was acquired over a typical (patient size
dependent) field of view of 340-380 mm using 6mm slices.  The in-plane pixel matrix was
216x256  and  parallel  imaging  (i-PAT factor  2)  was  applied,  along  with  bandwidth  977
Hz/pixel.  Images were typically acquired at a rate of two slices per breath hold (scan times
approximately 10-15 seconds) although this was reduced to a single slice per breath hold if a
shorter scan time was necessary.  The images were exported and the analysis was performed
off line sequence using CVI 42 (Circle Cardiovascular Imaging software, Calgary, Canada)
by  a  single  observer  who  was  blinded  to  randomised  therapy.  This  was  done  for  the
quantitative measurement  of LVM, EF, end-diastolic  volume (EDV), end-systolic  volume
(ESV), cardiac output (CO) and stroke volume (SV) which were derived by region of interest
contours  placed  around  endocardial  and  epicardial  LV  borders  at  end  systole  and  end
diastole.
Papillary  muscle  mass  was  included  in  the  LVM measurement  if  the  muscle  mass  was
continuous with the myocardial  wall.  Care was taken to ensure that the slice ranges were
matched for the baseline and final datasets even if it meant the removal of basal or apical
slices  to  allow accurate  slice  matching.  This  will  have  meant  an  underestimation  of  the
absolute LVM in some scans but ensured accurate comparison between the baseline and final
scans. LVM was indexed to body surface area, which were calculated using the Mosteller
formula and indexed to height, height1.7 and height2.7.
Short axis images using the same methods and pulse sequences as for the LV images were
also obtained from the atrioventricular ring to the base of the atria.  Left atrial volumes were
derived by region of interest contours placed around the left atrial endocardial borders at end
systole again using CVI 42 (Circle Cardiovascular Imaging software, Calgary, Canada). The
left atrial appendage and pulmonary veins were excluded from the left atrial volume. 
Reproducibility and Variability of MRI
We elected to use a single observer to undertake all of the segmentation work in order to
optimise the reproducibility since it is widely known that inter-observer variation tends to
introduce the greatest variability in these measurements.
Each  scan  was  analysed  at  least  twice  to  ensure  consistency,  a  third  measurement  was
conducted if the LVM varied by >5%. And the final measurement was taken as the average
of the two closest measurements. By recording the mean LVM in each case, this process lead
to  improved  confidence  that  the  actual  LVM  values  (and  changes)  were  correct  and
representative  of  genuine  change  -  i.e.  not  just  measurement  error.   From  these  paired
baseline measurements of LVM we calculated the intra-class correlation coefficient (ICC) to
be  0.99  and  we  obtained  an  intra-observer  test-retest  root-mean-square  coefficient  of
variation (RMS CoV) of 1.91%.
Abdominal MRI Protocol
An abdominal MRI was performed to assess subcutaneous and visceral abdominal fat mass.
Scout  images  were acquired in order to  localise  the full  structure of the abdomen in the
sagittal,  coronal  and  transverse  planes,  and  a  3D  dual-echo  Dixon  Volume  Interpolated
Breath hold Examination (Dixon VIBE) sequence was subsequently applied.  The sequence
was applied twice in the axial orientation covering the entire abdomen via two overlapping
3D blocks.  The pulse sequence imaging parameters were TR 3.67ms, TE 1.23 and 2.46ms,
flip-angle (FA) 9o and bandwidth  1040 Hz/pixel.   A total  of  166-192 slices  (matrix  size
169x320) were acquired over a field of view of 390x480 mm, and each slice was 3mm thick.
Each acquisition was performed in a single breath hold (typically 10 seconds) with the patient
holding their breath at end expiration.
Following the acquisition, the ‘fat-only’ images were visually inspected and any overlapping
slices  between  the  two  3D  datasets  were  removed.   The  remaining  images  were  then
combined  to  form  a  single  dataset  using  ImageJ  (U.  S.  National  Institutes  of  Health,
Bethesda, Maryland, USA) and the resulting file was exported for analysis using Analyze
(Version  12.0,  Mayo  Clinic,  Rochester,  MN).   The  analysis  was  performed  by  another
blinded observer. This was done in three steps, namely (i) application of baseline regions of
interest (ROI) to define sub-cutaneous adipose tissue structures (SCAT) and visceral adipose
tissue structures (VAT) using a manually chosen signal-intensity threshold; (ii) selection of
anterior and posterior segmentation boundaries - ranging from the top of the diaphragm to the
tip of the femoral heads; and (iii) manual removal of ‘non-abdomen’ structures (such as the
arms)  together  with other  non-visceral  structures  such as  bone marrow, renal  cortex  and
similar  soft-tissues.  Care was taken to ensure that the slice ranges were as consistent as
possible for the baseline and final datasets.  Our chosen rule was to ensure that on a per-
patient basis the slice ranges at each of the time-points were consistent to within 3 slices
(9mm).
For the abdominal adiposity, repeatability data were not derived specifically for this study
cohort but the scans underwent rigorous quality analysis prior to inclusion in the final data set
as detailed below.
Abdominal MRI Quality Analysis 
 The  images  from two participants  were  considered  to  be  of  sub-standard  quality,
based on problems associated with motion artefacts and uneven water suppression.
One  of  these  participants  was  omitted  from  the  study  entirely  (reducing  the
completing participants to n=60) and in the other case it was only possible to report
the VAT volume (i.e. SCAT volume was omitted).
 In n=7 of the largest participants,  it  was not  possible to include the entire  SCAT
volume within the 480mm FOV.  In n=2 of these cases the omitted SCAT regions
were deemed large enough to render the volumes as potentially unreliable.  In the
remaining n=5 cases, the omitted SCAT regions were extremely small (estimated to
be <5% of the total SCAT volume) and visually consistent across the two time-points.
Consequently, these participants were retained within the study. 
 Finally, there were n=7 cases where the radiographic overlap between the two slice
blocks on the baseline data was not quite sufficient.  However, it was a very simple
process to adjust the 12 month data analysis in order to exactly match the included
abdominal slices across both time-points.
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Visit 1 Screening *2 Baseline *3 follow-up 4 Follow-up^ *5 Follow-up *6 Last visit Annotations
Timeline - weeks
0 to -4 0
Within 4 weeks of 
screening visit
4†
(+/- 1 week)
17
(+/- 4 weeks)
34
(+/- 4 weeks)
(44-52)
(+/- 4 weeks)
* Participants were fasted for 
these visits. 
† At least 3 weeks after 
commencing study medication
 
‡U&E, FBC, LFT, cholesterol, 
Lipid  profile 
§ HbA1c, FIRI, glucose, 
NTproBNP, Leptin, hsCRP, 
Myeloperoxidase, N terminal 
Procollagen III peptide. A 
sample to be held for future 
genetics was also taken at the 
randomisation visit.
#The MRI scan could be 
performed ±3 weeks from the 
baseline visit and may therefore 
of required a separate visit 
although this was never 
required.
Informed Consent X
Medical History X
Demographics X
Concomitant Medications X X X X X X
Physical Examination X
Height & weight X
BP & P X X X X X X
Temperature X
ECG X
Echo X X
Safety Bloods‡ X X X X X X
Inclusion/Exclusion X
Pregnancy Testing if 
applicableΩ X X X X X X
Research Blood Sample § X X
Genetic blood sample X
24 hour BP X X
Cardiac & abdominal MRI# X X
Waist & hip measurement X X X X X
Adjustment of diabetes and 
BP medication X X X X
Record Adverse Events X X X X X
Randomisation X
Dispense Trial Drugs Xπ X X X
Return trial drugs X X X X
Table S1 An overview of all visits scheduled within the trial 
Table S2 Changes after 12 months dapagliflozin treatment in LVM and LVM indexed to BSA, Height, Height1.7, Height2.7 following sensitivity analysis
Variable Intention to Treat Analysis Per Protocol Analysis
Dapagliflozin
(n=32)
Placebo
(n=34)
†Difference
(95% CI)
P Value Dapagliflozin
(n=29)
Placebo
(n=33)
†Difference
(95% CI)
P Value
Primary Outcome 
Absolute LVM (g) -4.00 ± 0.87 -1.09 ± 0.84 -2.92 (-5.45 to -0.38) 0.025 -4.43 ± 0.93 -1.11 ± 0.86 -3.33 (-5.98 to -0.67) 0.011
Secondary Outcome
LVMi BSA (g/m2) -0.62 ± 0.38 -0.35 ± 0.37 -0.27 (-1.38 to 0.85) 0.634 -0.67 ± 0.42 -0.37 ± 0.39 -0.31 (-1.50 to 0.89) 0.610
LVMI Height (g/m) -2.37 ± 0.51 -0.67 ± 0.50 -1.70 (-3.20 to -0.21) 0.026 -2.62 ± 0.55 -0.68 ± 0.51 -1.94 (-3.50 to -0.37) 0.016
LVMI Height1.7 (g/m1.7) -1.65 ± 0.36 -0.48 ± 0.34 -1.17 (-2.21 to -0.13) 0.027 -1.82 ± 0.38 -0.49 ± 0.35 -1.33 (-2.41 to -0.24) 0.018
LVMI Height2.7 (g/m2.7) -0.98 ± 0.21 -0.30 ± 0.21 -0.68 (-1.30 to -0.06) 0.031 -1.08 ± 0.23 -0.31 ± 0.21 -0.77 (-1.42 to -0.12) 0.021
P-values in bold indicate P<0.05; † Estimated marginal mean difference between groups. All values expressed in estimated marginal mean ± standard error unless stated. 
Abbreviations: BSA, Body Surface Area; LVM, Left Ventricular Mass: LVMI, Left Ventricular Mass 
Variable LVMI to BSA Above Median LVMI to BSA Below Median Pinteraction
Dapagliflozin
(n=18)
Placebo
(n=15)
†Difference
(95% CI)
P Value Dapagliflozin
(n=14)
Placebo
(n=19)
†Difference
(95% CI)
P Value
Absolute LVM (g) -5.11 ± 4.87 -1.23 ± 4.80 -3.88 (-7.15 to -0.61) 0.021 -2.46 ± 4.57 -1.05± 4.47 -1.41 (-4.71 to 1.88) 0.395 0.228
LVMi BSA -1.02 ± 1.94 -0.39 ± 1.78 -0.64 0.376 -0.01 ± 2.64 -0.38± 2.64 0.36 0.616 0.973
(g/m2) (-2.07 to 0.79) (-1.08 to 1.80)
LVMI Height (g/m) -2.97 ± 2.79 -0.73 ± 2.70 -2.24
(-4.18 to -0.31)
0.024 -1.50 ± 2.86 -0.69± 2.74 -0.81
(-2.76 to 1.14)
0.408 0.303
LVMI Height1.7
(g/m1.7)
-2.03 ± 1.9 -0.50 ± 1.82 -1.53
(-2.88 to -0.18)
0.027 -1.06 ± 2.07 -0.51± 1.95 -0.55
(-1.91 to 0.81)
0.422 0.312
LVMI Height2.7
(g/m2.7)
-1.19 ± 1.10 -0.30 ± 1.04 -0.89
(-1.70 to -0.07)
0.034 -0.65± 1.31 -0.34± 1.21 -0.31
(-1.13 to 0.51)
0.446 0.327
Table S3 Changes in Measured Parameters on Cardiac MRI Analysed as Subgroups Above and Below Median LVMI to BSA after 12 months dapagliflozin treatment
P-values in bold indicate P<0.05; †Absolute mean Difference between groups.  All other values expressed in mean ± SD unless stated. * Median ± IQR
Abbreviations: LVM, Left Ventricular Mass; LVMI, Left Ventricular Mass indexed.
Table S4 Changes after 12 months dapagliflozin treatment in blood pressure after adjustment for baseline measurements
Intention to Treat Per Protocol 
Variable Dapagliflozin Placebo †Difference P Value Dapagliflozin Placebo †Difference P Value
(n=32) (n=34) (95% CI) (n=29) (n=33) (95% CI)
§ 24 hour SBP -2.58 ± 0.98 0.66 ± 0.97 (n=33) -3.24(-6.01 to -0.47) 0.023 -2.90 ± 1.45 0.72 ± 0.99 (n=32) -3.62(-6.52 to -0.72) 0.015
§24 hour DBP -0.79 ± 0.77 -0.09 ± 0.76 (n=33) -0.70(-2.88 to 1.48) 0.523 -0.89 ± 0.84 -0.07 ± 0.80 (n=32) -0.89(-2.56 to 0.78) 0.481
§Daytime SBP -2.22 ± 1.09 0.31 ± 1.07 (n=33) -2.53(-5.59 to 0.53) 0.104 -2.54 ± 1.16 0.40 ± 1.1 (n=32) -2.94(-6.15 to 0.26) 0.071
§Daytime DBP -0.84 ± 0.96 0.06 ± 0.94 (n=33) -0.89(-3.59 to 1.81) 0.511 -0.95 ± 1.43 0.08 ± 0.98 (n=32) -1.04(-3.91 to 1.83) 0.472
§Nocturnal SBP -3.12 ± 1.23 0.56 ± 1.23 (n=32) -3.68(-7.17 to -0.19) 0.039 -3.51 ± 1.31 0.64 ± 1.27 (n=31) -4.15(-7.83 to -0.47) 0.028
§ Nocturnal DBP -1.89 ± 0.85 -0.20 ± 0.85 (n=32) -1.69(-4.12 to 0.75) 0.171 -2.14 ± 0.91 -0.16 ± 0.88 (n=31) -1.98(-4.55 to 0.58) 0.127
Office SBP -5.08 ± 1.31 -1.99 ± 1.27 -3.09(-6.75 to 0.57) 0.096 -5.60 ± 1.39 -2.05 ± 1.30 -3.55(-7.36 to 0.27) 0.068
Office DBP -2.79 ± 1.12 -2.40 ± 1.09 -0.39(-3.52 to 2.74) 0.804 -3.07 ± 1.20 -2.48 ± 1.12 -0.59(-3.88 to 2.69) 0.720
P-values in bold indicate P<0.05; † Estimated marginal mean difference between groups. All values expressed in estimated marginal mean ± standard error unless stated. 
‡ One participant unable to tolerate any ambulatory blood pressure monitoring, § One further participant unable to tolerate overnight blood pressure monitoring. 
Abbreviations: DBP, Diastolic Blood Pressure; SBP, Systolic Blood Pressure.
Side Effect All patients Dapagliflozin Placebo P value
*Urinary Symptoms 15 8 7 0.434
†Confirmed UTI 7 1 6 0.011
Thrush 14 12 2 0.046
Dizzy/Postural Hypotension 1 0 1 0.378
$ Reported Hypoglycaemia 29 22 7 0.059
Thirst 4 2 2 0.631
Constipation 6 4 2 0.814
Serious Adverse Event 5 2 3 0.357
Table S5: Common SGLT2 inhibitor side effects in the two treatment arms
*Polyuria/Urinary Frequency
†Positive mid specimen stream urine
‡ Reported hypoglycaemia by patient based on symptoms and or confirmed by bm monitoring    
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Figure S3 : Trial Consort Diagram
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Figure S1: DAPA LVH trial hypothesis. 
Abbreviations: BP: Blood Pressure; EDV: End Diastolic Volume; FIRI: Fasting 
Insulin Resistance Index; HBA1C: Glycosylated Haemoglobin; hsCRP; High Sensitive 
CRP; LA: Left Atrial; LV: Left Ventricular; LVEF: Left Ventricular Ejection 
Fraction; LVH: Left Ventricular Hypertrophy; MPO: Myeloperoxidase; MRI: 
Magnetic Resonance Imaging; NTproBNP ; N Terminal pro B Type Natriuretic 
Peptide; PIIIP; Procollagen III .Peptide.
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Figure S2 Study design flowchart. 
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Figur
e S4 Scatter plot showing the effect of Dapagliflozin on ambulatory 24 hour and nocturnal systolic blood 
pressure
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Figure S5 Column mean graph with standard deviation error bars showing the effect of Dapagliflozin on VAT 
and SCAT volumes.
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Figure S6. Graph showing the effect of dapagliflozin over time on weight. 
Abbreviations: FV, Final Visit; RV, Randomisation Visit. 
